Ionis Pharmaceuticals, Inc. (IONS) Stock
Fundamentals
Recent news

Ionis Delivers Positive Late-Stage Results for Two Partnered Drugs
Ionis Delivers Positive Late-Stage Results for Two Partnered Drugs
IONS

Ionis announces positive interim data from partner Roche's Phase 3 IMAgINATION study in IgA nephropathy (IgAN)
Ionis announces positive interim data from partner Roche's Phase 3 IMAgINATION study in IgA nephropathy (IgAN)
IONS

Otsuka, Ionis' experimental ALS drug meets main goal in late-stage study
Otsuka, Ionis' experimental ALS drug meets main goal in late-stage study
IONS

Otsuka Announces Transformative Phase 3 FUSION Results for Ulefnersen, Bringing the FUS-ALS Community Closer to a Potential Targeted Treatment
Otsuka Announces Transformative Phase 3 FUSION Results for Ulefnersen, Bringing the FUS-ALS Community Closer to a Potential Targeted Treatment
IONS
Technicals
Analyst Ratings
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of -$0.78 for this quarter. The company has not yet shared when it is announcing earnings.
% positive news of 10 articles
published over the past 14 days
Latest news

Ionis Delivers Positive Late-Stage Results for Two Partnered Drugs
Ionis Delivers Positive Late-Stage Results for Two Partnered Drugs
IONS

Ionis announces positive interim data from partner Roche's Phase 3 IMAgINATION study in IgA nephropathy (IgAN)
Ionis announces positive interim data from partner Roche's Phase 3 IMAgINATION study in IgA nephropathy (IgAN)
IONS

Otsuka, Ionis' experimental ALS drug meets main goal in late-stage study
Otsuka, Ionis' experimental ALS drug meets main goal in late-stage study
IONS

Otsuka Announces Transformative Phase 3 FUSION Results for Ulefnersen, Bringing the FUS-ALS Community Closer to a Potential Targeted Treatment
Otsuka Announces Transformative Phase 3 FUSION Results for Ulefnersen, Bringing the FUS-ALS Community Closer to a Potential Targeted Treatment
IONS

Ionis announces positive topline results from Phase 3 FUSION study of ulefnersen marking significant milestone in advancing first potential disease modifying treatment for FUS-ALS
Ionis announces positive topline results from Phase 3 FUSION study of ulefnersen marking significant milestone in advancing first potential disease modifying treatment for FUS-ALS
IONS

Investors Dumped Ionis Pharmaceuticals Stock -- But Wall Street Hasn't Budged From Its Bullish Outlook
Investors Dumped Ionis Pharmaceuticals Stock -- But Wall Street Hasn't Budged From Its Bullish Outlook
IONS

Ionis Pharmaceuticals Eyes TRYNGOLZA Growth as Pipeline Faces Cardio Setbacks
Ionis Pharmaceuticals Eyes TRYNGOLZA Growth as Pipeline Faces Cardio Setbacks
IONS

Cathie Wood Is Loading Up on Ionis Pharmaceuticals (IONS) Stock. Here's the Bet She's Making.
Cathie Wood Is Loading Up on Ionis Pharmaceuticals (IONS) Stock. Here's the Bet She's Making.
IONS

Novartis' Del-desiran Fails Late-Stage DM1 Study, Shares Fall
Novartis' Del-desiran Fails Late-Stage DM1 Study, Shares Fall
IONS

How Novartis And Ionis' High-Profile Failure Reverberated Through Biopharma
How Novartis And Ionis' High-Profile Failure Reverberated Through Biopharma
IONS
About Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Brett P. Monia Ph.D. | Founder, CEO & Director | 1961 |
| Ms. Elizabeth L. Hougen M.A., M.B.A., M.S. | Executive VP of Finance & CFO | 1962 |
| Mr. Patrick R. O'Neil Esq. | Executive VP, Chief Legal Officer, General Counsel & Corporate Secretary | 1974 |
| Dr. Eric E. Swayze Ph.D. | Executive Vice President & Head of Research | 1966 |
| Mr. Brian Birchler | Executive Vice President of Corporate & Development Operations | 1966 |
| Dr. Richard S. Geary Ph.D. | Strategic Consultant | 1958 |
| Dr. Eugene Schneider M.D. | Executive VP, Chief Clinical Development & Operations Officer | 1973 |
| Mr. Darren Gonzales | Chief Accounting Officer & Senior VP | — |
| Dr. C. Frank Bennett BSc, Ph.D. | Executive VP & Chief Scientific Officer | 1957 |
| Mr. D. Wade Walke Ph.D. | Senior Vice President of Investor Relations | — |
Fundamentals
Valuation
Earnings Per Share
Income Statement
Dividend
Solvency
Technicals
What the experts say
15 Wall Street Analyst Ratings
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -0.1 | -5.1 | -19.7 | +18.8 | ||||||||
| 2022 | -2.5 | +5.9 | +8.7 | -5.5 | -4.8 | +3.1 | -1.3 | +13.4 | +1.8 | -1.8 | -9.0 | -6.0 |
| 2023 | +6.1 | -10.3 | -0.6 | +0.1 | +14.6 | -4.4 | +0.9 | -2.3 | +12.0 | +1.9 | +9.3 | -2.0 |
| 2024 | -2.8 | -11.3 | -4.6 | -6.1 | -12.6 | +22.9 | +5.0 | -7.1 | -15.3 | -1.7 | -7.8 | -3.2 |
| 2025 | -8.0 | +3.3 | -7.5 | +12.7 | +5.7 | +15.8 | +7.6 | -0.9 | +13.8 | +12.9 | +12.3 | -3.5 |
| 2026 | +3.8 | -2.3 | -8.4 | -0.5 | +1.6 | +5.2 | -34.6 | +10.8 | -25.7 |



